Tags

Type your tag names separated by a space and hit enter

Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study.

Abstract

PUFA from fish oil appear to have anti-inflammatory and anti-oxidative effects and improve nutritional status in cancer patients. With this as background, the aim of the present study was to investigate the effect of EPA plus DHA on inflammatory condition, and oxidative and nutritional status in patients with lung cancer. In our multicentre, randomised, double-blind trial, thirty-three patients with a diagnosis of advanced inoperable non-small-cell lung cancer and undergoing chemotherapy were divided into two groups, receiving four capsules/d containing 510 mg of EPA and 340 mg of DHA, or 850 mg of placebo, for 66 d. At the start of chemotherapy (T₀), after 8 d (T₁), 22 d (T₂) and 66 d (T₃), biochemical (inflammatory and oxidative status parameters) and anthropometric parameters were measured in both groups. A significant increase of body weight in the n-3 group at T₃ v. T₀ was observed. Concerning inflammation, C-reactive protein and IL-6 levels differed significantly between the n-3 and placebo groups at T₃, and progressively decreased during chemotherapy in the n-3 group, evidencing n-3 PUFA anti-inflammatory action. Concerning oxidative status, plasma reactive oxygen species levels increased in the placebo group v. the n-3 group at the later treatment times. Hydroxynonenal levels increased in the placebo group during the study, while they stabilised in the n-3 group. Our data confirm that the continual assumption of EPA plus DHA determined an anti-inflammatory and anti-oxidative action which could be considered a preliminary goal in anti-cachectic therapy.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Clinical Nutrition, San Giovanni Battista Hospital, Turin, Italy. cfinocchiaro@molinette.piemonte.it

    , , , , , , , , , , , , , ,

    Source

    The British journal of nutrition 108:2 2012 Jul pg 327-33

    MeSH

    Anti-Inflammatory Agents, Non-Steroidal
    Antineoplastic Agents
    Antineoplastic Combined Chemotherapy Protocols
    Antioxidants
    C-Reactive Protein
    Carcinoma, Non-Small-Cell Lung
    Cisplatin
    Combined Modality Therapy
    Deoxycytidine
    Dietary Supplements
    Docosahexaenoic Acids
    Double-Blind Method
    Eicosapentaenoic Acid
    Fatty Acids, Omega-3
    Female
    Humans
    Interleukin-6
    Lung Neoplasms
    Male
    Oxidative Stress
    Patient Dropouts
    Weight Gain

    Pub Type(s)

    Journal Article
    Multicenter Study
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    22114792

    Citation

    Finocchiaro, Concetta, et al. "Effect of N-3 Fatty Acids On Patients With Advanced Lung Cancer: a Double-blind, Placebo-controlled Study." The British Journal of Nutrition, vol. 108, no. 2, 2012, pp. 327-33.
    Finocchiaro C, Segre O, Fadda M, et al. Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study. Br J Nutr. 2012;108(2):327-33.
    Finocchiaro, C., Segre, O., Fadda, M., Monge, T., Scigliano, M., Schena, M., ... Canuto, R. A. (2012). Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study. The British Journal of Nutrition, 108(2), pp. 327-33. doi:10.1017/S0007114511005551.
    Finocchiaro C, et al. Effect of N-3 Fatty Acids On Patients With Advanced Lung Cancer: a Double-blind, Placebo-controlled Study. Br J Nutr. 2012;108(2):327-33. PubMed PMID: 22114792.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study. AU - Finocchiaro,Concetta, AU - Segre,Olivia, AU - Fadda,Maurizio, AU - Monge,Taira, AU - Scigliano,Mara, AU - Schena,Marina, AU - Tinivella,Marco, AU - Tiozzo,Elisa, AU - Catalano,Maria G, AU - Pugliese,Mariateresa, AU - Fortunati,Nicoletta, AU - Aragno,Manuela, AU - Muzio,Giuliana, AU - Maggiora,Marina, AU - Oraldi,Manuela, AU - Canuto,Rosa A, Y1 - 2011/11/25/ PY - 2011/11/26/entrez PY - 2011/11/26/pubmed PY - 2012/9/28/medline SP - 327 EP - 33 JF - The British journal of nutrition JO - Br. J. Nutr. VL - 108 IS - 2 N2 - PUFA from fish oil appear to have anti-inflammatory and anti-oxidative effects and improve nutritional status in cancer patients. With this as background, the aim of the present study was to investigate the effect of EPA plus DHA on inflammatory condition, and oxidative and nutritional status in patients with lung cancer. In our multicentre, randomised, double-blind trial, thirty-three patients with a diagnosis of advanced inoperable non-small-cell lung cancer and undergoing chemotherapy were divided into two groups, receiving four capsules/d containing 510 mg of EPA and 340 mg of DHA, or 850 mg of placebo, for 66 d. At the start of chemotherapy (T₀), after 8 d (T₁), 22 d (T₂) and 66 d (T₃), biochemical (inflammatory and oxidative status parameters) and anthropometric parameters were measured in both groups. A significant increase of body weight in the n-3 group at T₃ v. T₀ was observed. Concerning inflammation, C-reactive protein and IL-6 levels differed significantly between the n-3 and placebo groups at T₃, and progressively decreased during chemotherapy in the n-3 group, evidencing n-3 PUFA anti-inflammatory action. Concerning oxidative status, plasma reactive oxygen species levels increased in the placebo group v. the n-3 group at the later treatment times. Hydroxynonenal levels increased in the placebo group during the study, while they stabilised in the n-3 group. Our data confirm that the continual assumption of EPA plus DHA determined an anti-inflammatory and anti-oxidative action which could be considered a preliminary goal in anti-cachectic therapy. SN - 1475-2662 UR - https://www.unboundmedicine.com/medline/citation/22114792/full_citation L2 - https://www.cambridge.org/core/product/identifier/S0007114511005551/type/journal_article DB - PRIME DP - Unbound Medicine ER -